On Sept. 18th 2013, $AMBS CEO met with Becton Dickinson's Custom Technology Team (CTT) accompanied by Corporate Advisor Dr. Adam Simon
The Sept. 18th meeting between Amarantus and Becton Dickinson's Custom Technology Team went very well
Many important business & scientific topics were discussed, including the current status of the assay, & ways to improve its marketability
The assay is currently performing very well, and BD expects to deliver the final report on this phase of the project in the next 2 weeks.
BD's analytical performance report for the assay is awaiting final approval prior to distribution to Amarantus
Gerald indicated that news would be released before the end of the third quarter. Gerald typically follows through on his statements.